Belimumab
- Generic Name
- Belimumab
- Brand Names
- Benlysta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 356547-88-1
- Unique Ingredient Identifier
- 73B0K5S26A
- Background
Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE). By binding to BLyS and blocking its intera...
- Indication
In the US, belimumab is indicated to treat active systemic lupus erythematosus (SLE) and active lupus nephritis in patients aged five years and older who are receiving standard therapy. In Europe, belimumab is also used to treat SLE and lupus nephritis but only in adults.
...
- Associated Conditions
- Active Systemic Lupus Erythematosus, Lupus Nephritis
- Associated Therapies
- -
A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT00583557
- Locations
- 🇺🇸
University of Pittsburgh School of Medicine & ASPH, Pittsburgh, Pennsylvania, United States
🇺🇸Wallace Rheumatic Disease Center, Los Angeles, California, United States
🇺🇸IPC Clinical Research, Ogden, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.